Instrumento Inactivo

Otros idiomas HLS Therapeutics Inc Toronto S.E.

Acciones

AM

CA05328X1015

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

National Bank on DRI Healthcare Trust's Xenpozyme Royalty Stream Acquisition	02/07
HLS Therapeutics Sells Xenpozyme Royalty Interest to DRI Healthcare Trust	02/07
HLS Therapeutics Brief: Announcing Sale of its XENPOZYME Royalty Interest to DRI Healthcare Trust	02/07
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust	02/07
HLS Therapeutics Reports Annual Meeting Results	08/06
HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study	28/05
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	28/05
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment	28/05
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	09/05
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.	09/05
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	09/05
HLS Therapeutics Announces Q1 2024 Financial Results	09/05
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	09/05
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call	25/04
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.	12/04
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	12/04
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	08/04
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	08/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas HLS Therapeutics Inc Toronto S.E.

Acciones

AM

CA05328X1015

Otros idiomas

Filtros